Author

Lindsay Robusto

Institution: The University of Texas MD Anderson Cancer Center

Observed institution: The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-8607-3539

Observed ORCID: 0000-0002-8607-3539

OpenAlex ID: A5019088285

Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia

2024 · Jiasen He, Faryal Munir, et al. · Cancers · 15

Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies

2023 · Faryal Munir, Jiasen He, et al. · Translational Pediatrics · 10

Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia

2024 · Amber Gibson, Cesar Nunez, et al. · Haematologica · 7

Current and emerging pharmacotherapy for the treatment of childhood acute myeloid leukemia

2022 · Branko Cuglievan, David McCall, et al. · Expert Opinion on Pharmacotherapy · 4

Revumenib in Pediatric Acute Leukemia: Clinical Activity and Differentiation Syndrome from the AUGMENT-101 Study

2026 · Branko Cuglievan, Samanta Catueno, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 5

Citation count: 36

H-index: 4

I10-index: 2